Skip to Main Content

Axovant Sciences (AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix (ZGNX) and Amicus Therapeutics (FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.